Developments are heating up on the regulatory front with regard to Outlook Therapeutics’ bid to become the first company to secure EU marketing approval for an ophthalmic formulation of bevacizumab.
Outlook’s investigational product, brand name Lytenava (ONS-5010), for wet age-related macular degeneration (wet AMD), is listed as being up for...








